Search the Newsreel

TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics

SueWallSt is investigating potential securities claims against Tenax Therapeutics (TENX) after its shares dropped 84-85% following the failure of its Phase 3 LEVEL trial of TNX-103 to meet primary and key secondary endpoints. Investors who suffered losses due to this decline are encouraged to …

Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX)

Levi & Korsinsky, LLP has announced an investigation into Tenax Therapeutics (TENX) after the company's stock value dropped significantly following the failure of its Phase 3 LEVEL trial for TNX-103. Shareholders who lost money are encouraged to submit their information as the firm investigates …

Adage Capital discloses 6.81% Tenax Therapeutics (TENX) stake via stock and warrants

TENAX THERAPEUTICS INC : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING

William Blair has downgraded its rating for Tenax Therapeutics Inc. (TENX.O) to "Market Perform." This change in rating suggests a revised outlook on the company's stock performance. The article does not provide specific reasons for the downgrade but notes the financial analyst action.

Evercore ISI Downgrades Tenax Therapeutics to In Line From Outperform, Adjusts PT to $5 From $39

Evercore ISI has downgraded Tenax Therapeutics (TENX) from Outperform to In Line and significantly reduced its price target from $39 to $5. This downgrade follows similar actions by other firms, coming after Tenax Therapeutics announced disappointing topline results from its Phase 3 LEVEL clinical …

Tenax Therapeutics’ stock crashes on Phase III trial failure

Tenax Therapeutics' stock plunged by nearly 90% after its Phase III LEVEL trial for TNX-103, an oral therapy for pulmonary hypertension associated with heart failure, failed to meet its primary and key secondary endpoints. Despite the overall failure, a prespecified subgroup analysis showed a …

TENAX THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $4 FROM $26

LEERINK PARTNERS has significantly cut its target price for TENAX THERAPEUTICS INC (TENX.O) from $26 to $4. This adjustment in the target price indicates a revised outlook for the company by the financial firm. The article, sourced from Reuters, focuses solely on this financial …

Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors: Johnson Fistel Investigates Potential Securities Law Violations After Phase 3 Trial Failure; Shares Plummet Nearly 90%

Johnson Fistel, PLLP is investigating potential federal securities law violations by Tenax Therapeutics, Inc. (NASDAQ: TENX) after the company announced its Phase 3 LEVEL clinical trial failed to meet its primary and key secondary endpoints. Following this news, Tenax shares dropped by nearly 90%. …

Tenax Therapeutics (NASDAQ:TENX) Sets New 52-Week Low - Here's Why

Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback

Tenax Therapeutics (NASDAQ: TENX) stock dropped significantly after its Phase 3 LEVEL study for oral levosimendan (TNX-103), a heart failure drug, missed its primary and key secondary endpoints. Despite this setback, subgroup analyses showed promising results in patients with greater disease severity and a …

Tenax Therapeutics (TENX) Stock Plummets 87% Amid Clinical Setba

Tenax Therapeutics Inc. (TENX) Stock Price | Live Quotes & Charts | NASDAQ

This article provides live quotes and charts for Tenax Therapeutics Inc. (TENX) stock, showing its current price of $1.77, a decrease of 86.83%. It notes that there are no analyst ratings or earnings information currently available for the company. The page also includes disclaimers …

TENX Stock Whipsaws As Traders Target Volatile Setup

TENX Stock Whipsaws As Traders Eye Volatility And Cash Pile

Tenax Therapeutics Inc. (TENX) stock has experienced extreme volatility, dropping 85.95% recently, despite holding over $117 million in cash and no debt. The company is burning through cash with significant operating losses, typical of a high-risk biotech profile. Traders are attracted to TENX for …

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

Tenax Therapeutics announced topline results from its Phase 3 LEVEL clinical trial for TNX-103 in PH-HFpEF patients, revealing that the primary endpoint of improved 6-minute walk distance was not met. However, prespecified exploratory analyses showed significant reductions in NT-proBNP and right ventricular systolic pressure, …

Tenax Therapeutics (NASDAQ:TENX) Drops 85% as Phase 3 LEVEL Study Fails to Meet Main Endpoints

Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout

Investing.com - U.S. stock index futures edged higher on Monday, while Dow futures were little changed, as investors scaled back hopes for a breakthrough in the Middle East and looked ahead to key inflation data due later this week for fresh clues on the …

Tenax Therapeutics (TENX) Reports Phase 3 LEVEL Trial Results, F

Tenax Therapeutics’ heart drug misses main goal in study, shares plunge

Tenax Therapeutics' experimental drug TNX-103 failed to significantly improve walking distance in a late-stage trial for a difficult-to-treat form of heart failure, causing shares to plunge over 85%. While the drug missed its primary and a key secondary goal, a subgroup of patients with …

Tenax Therapeutics reports Phase 3 LEVEL topline: missed primary but strong biomarker and subgroup signals

Tenax Therapeutics announced that its TNX-103 drug in the LEVEL Phase 3 trial missed its primary endpoint (6MWD). However, the drug demonstrated strong biomarker signals with a 49% reduction in NT-proBNP and significant improvement in a prespecified subgroup of patients with baseline 6MWD less …

Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint

Orion's license partner, Tenax Therapeutics, announced that its Phase 3 LEVEL trial for oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not meet its primary endpoint of improved 6-minute walk distance. However, subgroup analyses showed a beneficial …

Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103

Tenax Therapeutics announced that its Phase 3 LEVEL trial for TNX-103, targeting pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), failed to meet its primary and key secondary endpoints. Despite the overall trial failure, prespecified subgroup analyses showed potential benefits for …

(TENX) Price Dynamics and Execution-Aware Positioning

This article provides an AI-driven analysis of Tenax Therapeutics Inc. (NASDAQ: TENX), highlighting weak near and mid-term sentiment that could challenge a positive long-term outlook. It details three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss levels. The …

Tenax Therapeutics (TENX) to Release Quarterly Earnings on Wednesday

LifeSci Capital Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Maintains Target Price $35

LifeSci Capital has reiterated its Buy rating for Tenax Therapeutics (TENX.US) and maintained its target price at $35. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

Tenax Therapeutics: Double Or Nothing (Rating Upgrade)

Perceptive Advisors LLC Raises Stock Holdings in Tenax Therapeutics, Inc. $TENX

Chardan Capital Initiates a Buy Rating on Tenax Therapeutics (TENX)

Chardan Capital analyst Gautam Chukka has initiated coverage of Tenax Therapeutics (TENX) with a Buy rating and a $27.00 price target. This aligns with a strong Buy consensus from other analysts, with an average price target of $37.29. The company recently reported a GAAP …

Tenax Therapeutics (NASDAQ: TENX) ends Q2 2026 with $118M cash

Tenax Therapeutics (NASDAQ: TENX) reported a net loss of $17.8 million for Q2 2026 and $33.5 million for the first half of 2026, primarily due to increased R&D spending on its Phase 3 LEVEL and LEVEL-2 clinical trials for oral levosimendan. The company ended …

Tenax Therapeutics reports Q2 net loss $17.8M, cash $118.0M; LEVEL Phase 3 topline due Aug 2026

Tenax Therapeutics reported a Q2 2026 net loss of $17.8 million and held $118.0 million in cash. The company increased R&D spending to $12.9 million as it advances two Phase 3 trials for oral levosimendan, with topline data from the LEVEL trial expected in …

Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tenax Therapeutics reported its second-quarter 2026 financial results, highlighting a cash position of $118.0 million and an extended cash runway through Q2 2028 due to warrant exercises. The company anticipates releasing topline data from its Phase 3 LEVEL clinical trial in August 2026 and …

Tenax Therapeutics: Q2 Earnings Snapshot

This article provides a brief snapshot of Tenax Therapeutics' Q2 earnings. No specific financial details are available in the provided content. The article is very short and serves as an announcement for the earnings report.

Stempoint Capital LP Acquires Shares of 188,700 Tenax Therapeutics, Inc. $TENX